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Abstract 
Introduction: Osteoporotic hip fractures are 
common in elderly. There is increased risk of sustaining 
other fractures that incur financial burden on the health 
system. Prescription of bisphosphonates after 
osteoporotic hip fracture surgery has been shown to 
reduce the overall incidence of re-fractures. 
Methods: All osteoporotic hip fractures treated 
surgically in Mater Dei Hospital in the year 2011 were 
analysed in this observational retrospective study. The 
inclusion criteria were all primary osteoporotic hip 
fractures. The initiation, or not, of anti-osteoporotic 
treatment upon discharge from hospital was reviewed.  
The mortality and re-fracture rate of this cohort was 
reviewed for a period of 3 years. The cost of 
hospitalization for hip fracture and re-fractures was 
calculated based on local health services costs and 
compared to the benefits of providing a free 
bisphosphonate medication to each patient.  
Results: The osteoporotic hip fracture care pathway 
did not include initiation of anti-osteoporotic therapy 
after operations.  A re-fracture rate of 11.7% over three 
years predominantly in female patients was observed.  In 
the first year following hip fracture, an estimated direct 
medical health expenditure due to re-fractures was of 
€37,642.55 - €48,835.19.  
Conclusion: Prescribing a bisphosphonate has been 
found to reduce both the re-fracture and mortality rates.  
In our study, a bisphosphonate prescription could have 
reduced the all cause mortality rate of 25.3% to 15.18% 
over the first year of hip fracture, as well as reduced the 
financial and social burden incurred due to a re-fracture.    
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Introduction 
In an aging population, bone mass is progressively 
lost in a physiological process, resulting in an increased 
risk of a fracture following minor trauma. The 
commonest osteoporotic fractures are at the neck of the 
femur (hip), vertebral body and forearm.1  
The most important osteoporosis-related fractures 
from a public health perspective are hip fractures.2-3 In 
2000, there were 0.89 million osteoporotic hip fractures 
in Europe. An estimated 179,000 men and 611,000 
women are expected to sustain a hip fracture each year 
in European countries.4-5 Hip-fractures due to 
osteoporosis were related to the highest medical costs 
incurred on the health services.6 An estimated 820 
million pounds Sterling per year was attributed to 
osteoporotic hip fractures in the United Kingdom.7 
Hip fractures are associated with a high mortality of 
10-20% as well as morbidity.8-9 It is common knowledge 
that these elderly patients often lose a substantial amount 
of their daily independence after a hip fracture with 25 - 
50% of them requiring residential help or nursing 
homes.10-11 
Patients run a cumulative risk for further 
osteoporotic fractures after suffering a hip fracture.12-13 
Therefore osteoporosis-targeting treatment should be 
prescribed to all patients with previous history of 
osteoporotic fractures as stated by both the national 
institute for health and care (NICE) and the Scottish 
intercollegiate guideline network (SIGN).14-15  
Bisphosphonates are considered to be the gold 
standard first line treatment in established 
osteoporosis.16 They are also recommended in treating 
patients who have suffered an osteoporotic hip fracture. 
Calcium and Vitamin D may also serve as good 
supplements in elderly with hip fractures since vitamin 
D deficiency contributes to loss of bone in advanced 
age.17 This is more prevalent than one would suspect 
even in countries like Malta where natural sunlight is in 
abundance. Yet, starting patients on anti-osteoporotic 
treatment prior to discharge is not part of the standard 
management plan in Malta.  
Physicians need to be on the look out for factors 
that may lead to secondary osteoporosis and therefore 
resulting into fractures including thyroid disease, 
alcoholism, steroid therapy and malignancy.20 There 
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have been mixed conclusions whether warfarin should 
also be considered as a predisposing factor to 
fractures.22-23  
The aims of this study were to evaluate the current 
practice in Malta when it comes to prescribing anti-
osteoporotic treatment following hip fracture surgery as 
well as: 
1) Find the incidence of further osteoporotic fractures 
following a primary hip fracture; 
2)  Evaluate the costs involved in treating patients 
suffering an osteoporotic hip fracture. 
3) Run a cost effectiveness comparison between the 
cost of prescribing anti-osteoporotic medication 
versus the cost of managing secondary fractures in 
the same patients suffering a primary osteoporotic 
hip fracture.  
Permissions from Mater Dei Hospital chief 
executive officer and data protection office were 
obtained. Ethical approval was granted in accordance to 
the Declaration of Helsinki from the University of Malta 
Research and Ethics Committee.  
 
Method 
An observational retrospective study was performed 
analyzing all emergency osteoporotic hip fractures 
requiring surgery, presenting to Mater Dei Hospital, 
Malta, between January to December 2011. With the 
permission of the Chairman of the Department of 
Trauma and Orthopaedics as well as the Central 
Performance Unit (CPU), the operated hip fractures list 
was obtained. Mortality data was obtained from the 
Department of Health Information and Research.  
The inclusion criteria for our study were patients 
over 60 years of age suffering a hip fracture following a 
low energy hip fracture. A low energy hip fracture was 
defined as a fracture suffered after minimal or low 
trauma. These were considered to be osteoporotic in 
nature. 21 
The exclusion criteria were those patients that were 
on long-term steroids, patients who consume large 
amounts of alcohol (over 3 units daily in males, over 2 
units daily in females), had a history of malignancy, 
hypothyroidism or were on warfarin as well as those 
sustaining a high-energy trauma. 
Using the ‘Electronic Case Summary’ software, 
which is a software used at Mater Dei Hospital on which 
discharge summaries are stored, each patient having 
undergone an osteoporotic hip surgery was analyzed as 
to the mechanism of injury and the management he/she 
was discharged on, with special attention to whether any 
anti-osteoporotic medication was prescribed.  The 
picture archiving and communication system (PACS) 
was used to evaluate whether each patient re-presented 
to a state health care institution with another 
osteoporotic fracture over a period of 3 years following 
the primary hip fracture.  
Data was stored in a spreadsheet and statistical 
analyses were performed using SPSS IBM v.11.  An 
independent t-test evaluated the significance of age and 
gender in relation to hip fractures, while spearman’s 
correlation co-efficient test was used to compare age and 
length of stay in hospital.  The cost of hospitalization 
(including doctors, nurses, x-rays, bloods, 
electrocardiogram and physiotherapy) per night, major 
operation, intermediate operation costs and doctor 
consultation at outpatients at Mater Dei Hospital was 
obtained from the billing section of the hospital. Table 1 
represents the itemized cost of each service.  
 
Table 1:  Represents the itemized cost per service 
* Cost based on 2014 prices. 
** Hospitalisation cost include in-patient doctors and 
nurses care, X-rays, Blood tests, ECG and 
Physiotherapy. 
 
These costs were used to calculate the mean cost 
per patient who presented with a hip fracture as well as 
cost per re-fracture either requiring conservative 
management or an operation. The cost was calculated 
following the standard medical practice (as below) 
performed at the Department of Trauma and 
Orthopaedics, Mater Dei Hospital for each type of re-
fracture.  
The cost was calculated on the basis of an 
admission to hospital with a mean length of stay 
according to the type of fracture incurred and requiring 
an operation as follows; 11 days Hip fractures; one day 
Vertebral fractures; three days Humeral fracture; two 
days Radial fracture. The cost for radial and humeral re-
fractures was calculated on the basis of either requiring 
an operation or just following a conservative 
management. Follow-up appointments were considered 
as follows: Conservative management of humeral and 
radial fractures requiring two follow-up appointments 
while one follow-up appointment after operative 
management. This is the standard protocol of follow up 
in our institution. Both humeral and radial fracture 
operations were considered as intermediate operations 
whilst hip fracture as major operations.  
Service* Cost  
Hospitalisation**  €256.23/night 
Intermediate Operation (Radial & 
humeral fractures) €1048.22 / operation 
Major Operation (Hip fracture) €2329.37/ operation 
Doctor consultation at outpatients €36.94/visit 
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All costs excluded accident and emergency services 
and only considered direct medical costs.  
 
Results 
In 2011, there were 370 admissions (280 females 
and 90 males) to Mater Dei Hospital, Malta, between the 
ages of 60 and 99 years that required an orthopaedic hip 
operation.  Out of which, 89 were excluded due to the 
presence of risk factors predisposing them to fractures. 
The remaining 281 (226 females and 55 males) were 
considered to have sustained an osteoporotic hip 
fracture, with most fractures occurring in females 
between the age of 79 and 87 years (p=0.0001).  
The length of stay at hospital from day of admission 
to discharge ranged from three days to 51 days with a 
mean stay of 11 days. Figure 1 is a histogram that shows 
the length of stay of all patients with an osteoporotic hip 
fracture during the study period. The length of stay 
within hospital showed no co-relation with age 
(p=0.069); or with age and gender (females p=0.212; 
males p=0.793). The calculated mean bed cost, hip 
operation and follow-up (as discussed above) for an 
osteoporotic hip fracture was of €5,182.84.  
None of the patients who sustained an osteoporotic 
hip fracture were started on a bisphosphonate or a 
calcium supplement by the responsible caring team. The 
only few patients, three in total, on anti-osteoporotic 
supplements had already been on this treatment prior to 
suffering the initial hip fracture.  
Over three years, 11.7% (n=33) presented to a state 
health institute with a re-fracture with the majority being 
female (n=25) and the most common fracture being a 
fracture to the contralateral hip. Figure 2 shows the re-
fracture presentation per year over three years according 
to gender. Figure 3 represents the cumulative re-
fractures over three years post-hip fracture, while Figure 
4 shows the types of re-fractures sustained over three 
years.  
The re-fracture rate over a year from the index hip 
fracture surgery was of 6% (n=17). Table 2 represents 
the direct medical cost per re-fracture type and the cost 
sustained over the three years due to re-fractures in the 
population under study.  
 
Figure 1: Histogram showing length of stay at hospital from admission to post-surgery discharge 
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Figure 2: Presents the re-fractures per year over 3 years according to gender 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Cumulative re-fracture rate over 3 years 
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Figure 4: Different type of secondary fracture after the index hip fracture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Represents the direct medical cost per fracture management and the total cost incurred per fracture over the 3 
years due to re-fractures 
 
Type of fracture 
Cost per fracture 
in Euro 
 N 
Direct medical cost 
incurred due to fractures 
over 3 years in Euro 
Hip fracture 5,182.84  14 72,559.76 
Vertebral fracture 291.17  6 1,747.02 
Humeral fracture 
(Conservative) 
69.88  4* 279.52 
Humeral fracture 
(Operative) 
1,851.85  4* 7,407.40 
Distal radius fracture 
(Conservative) 
69.88  9* 628.92 
Distal radius fracture 
(Operative) 
1,595.62  9* 14,360.58 
* Cost for both conservative and operative management was calculated but in actual fact only one of the management 
plans was followed for these patients. 
 
Discussion  
Low-energy trauma causing a fracture in a major 
bone is a sign of bone fragility. Osteoporotic hip 
fractures are the most severe and serious results of 
osteoporosis. 22 The determining factors for osteoporotic 
fractures are a combination of bone strength and risk of 
falls. 23  
Our study evaluated low-energy traumatic hip 
fractures within the adult population of 60 years and 
over presenting to the only general hospital in the island. 
  
 Although private clinics are available, hip fractures 
are generally referred to Mater Dei hospital for 
management. Therefore this study can be considered as a 
population-based study over a period of one year. Since 
no patients were started on bisphosphonates post-
osteoporotic hip fracture surgery, it was impossible to 
present a case-control study for possible re-fracture 
outcomes.  
The majority of the patients presenting with an 
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osteoporotic hip fracture were female, which follows the 
findings of Couris CM et al. who stated that women 
aged 60 to 85 years, have increased risk of hip fractures. 
24 Those elderly patients with a previous history of an 
osteoporotic hip fracture are at higher risk to develop 
other fractures later on. These elderly patients have a 
2.5-fold increased risk of suffering vertebral fractures 
and 2.3-fold risk for further hip fractures.25 This could 
be seen in our study where 11.7% (n=33) of the adult 
population under study experienced a re-fracture with 14 
patients sustaining a fracture of the other hip, followed 
by nine patients exhibiting a distal radius fracture. 
Females showed a higher incidence of re-fractures when 
compared to males.  
Once a hip fracture has been sustained, the quality 
of life decreases and the mortality increases by about 
20%. 26 A hip fracture does not only have a negative 
impact on the quality of life of the patient but also on 
his/her family and society. It also implies an economic 
burden on the national health system (NHS), which in 
Malta amounts to a mean direct cost of €5,182.84 per 
osteoporotic hip fracture when there is a hospital stay of 
11 days. Sustaining a re-fracture will further increase the 
negative impact on the patient as well as medical costs 
incurred by the NHS. A hip fracture has direct 
consequences on the patient himself apart from carrying 
a direct financial burden on the national health system. 
The study aimed to evaluate the direct costs incurred 
from the moment of hospitalization up to discharge from 
acute care. It is virtually impossible to calculate all the 
indirect costs including days off work (both by patients 
and relatives), rehabilitation costs, possible surgery 
related complications requiring further hospital 
readmissions, household alterations in order to render 
them more fall proof etc. All these hidden costs increase 
the overall expenditure dramatically.  
Within a year the re-fracture rate was of 6% of the 
total population under study, with direct mean medical 
costs estimations ranging between €37,642.55 to 
€48,835.19, depending whether a conservative or an 
operative management plan was followed. In actual fact 
the total costs would be much greater due to indirect 
costs as well emergency services and rehabilitation, 
which were excluded. The estimated cost is based on 
whether the distal radial fractures and the vertebral 
fractures followed a conservative care pathway or a 
surgical pathway, in which case the cost would vary as 
discussed above. Only the financial aspect was taken 
into consideration. It is immediately obvious, that 
several patients and their relatives undergo a physically 
and psychologically painful experience. In fact, 24% 
(n=8) of the patients in the study, died after their re-
fracture, within a three-year follow up period. Three 
patients passed away within three months of the second 
fracture.  
The total all-cause mortality rate after one year of 
the index osteoporotic hip fracture was of 25.3%, with 
two of these patients having a re-fracture and dying 
within the first year. Therefore it is important to try to 
prevent such re-fractures from occurring by securing a 
number of measures. One simple way is prescribing anti-
osteoporotic treatment. The aim of starting therapy is to 
prevent the re-fracture rate as well as improve the 
quality of life. Unfortunately a large amount of patients 
with hip fractures are not prescribed any anti-
osteoporotic treatment.22 This is the case in Mater Dei 
Hospital, Malta, where none of the osteoporotic hip 
fracture patients post-surgery were prescribed anti-
osteoporotic treatment. Unfortunately there has not been 
any change in the management plan to date and no 
preventive policies or funding for osteoporotic drugs 
been implemented. It is hoped that this study will 
stimulate policy makers to implement this widely 
accepted international preventive management.   
A study conducted in Belgium showed that only 6% 
of patients with hip fractures were discharged with anti-
osteoporotic medication.5 The same situation was found 
in the United States, where only 6.6% of the patients 
with hip fractures were prescribed calcium and vitamin 
D supplements and 7.3% were prescribed anti-
osteoporotic agents.27 This lack of anti-osteoporotic 
therapy prescription among the orthopedic community 
can be described as ‘Clinical inertia’ that is defined as 
“failure of healthcare providers to initiated or change 
treatment when the health status of the patient indicates 
such action is necessary”.28 This clinical inertia is having 
a negative impact both directly and indirectly to the 
economic situation in the country leading to a financial 
burden on the health and social services.  
Different types of bisphosphonates have shown to 
decrease the incidence of hip fractures in women who 
are osteoporotic as well as increase bone density in the 
femoral neck and lumbar spine.29, 30 Bisphosphonates 
both orally and intravenously have shown a reduction in 
mortality rate after an osteoporotic hip fracture. It was 
reported that oral bisphosphonates could lead to a 
relative reduction of 60% death per year.31, 32 Although 
one must keep in mind the complications that may arise 
from their usage such as necrosis of the jaw and upper 
gastrointestinal side effects.33 
Bisphosphonates for osteoporotic fractures are not 
part of the free medication scheme entitlement in Malta, 
so if prescribed by the orthopaedic team, the patient will 
have to incur the cost. Considering alendronic acid 
monthly tablets at retailed price from a pharmacy in 
Malta for a year supply would cost €117.12 per 
individual. If this was provided as part of the discharge 
requirements and entitlement to every patient leaving the 
NHS after sustaining an osteoporotic hip fracture during 
the study period (n = 281), the cost would have 
amounted to €49,770.72 per year. At retail price this 
would have cost the NHS €935.53 more than the re-
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fracture management direct medical expense incurred. It 
is important to consider that the wholesale price of this 
drug to the NHS would be much cheaper. Also one 
needs to consider the fact that the indirect costs and 
rehabilitation costs were not included, so one can still 
suggest that providing a bisphosphonate to every patient 
sustaining an osteoporotic hip fracture is more 
economical and socially beneficial. Keeping in mind that 
following the osteoporotic hip fracture there was an all-
cause mortality rate of 25.3%, prescribing of a 
bisphosphonate might have reduced this percentage by 
60% 31-32, where 43 patients would have survived the 
first year post- hip fracture out of the 71 patients that 
died. The cost effectiveness of bisphosphonates is a 
well-established fact with multiple repeated studies 
published in the literature. The effectiveness takes 
between six to twelve months to be evident on bone 
mineral density measurement, and is effective up to ten 
years post continuous treatment. 34-36  
 
Study limitation 
Our study investigated only patients that presented 
to the state health care institutes, where the national 
PACS is only available, so re-fractures presenting to 
private clinics or hospitals have been excluded in the 
study. The mechanism of injury, risk factors and 
treatment on discharge of each patient were based on 
case summaries that were written by doctors working in 
the orthopaedic department, therefore information could 
have been subject to human errors. The medical costs 
quoted are calculated according to the local NHS 
expenses at 2014 and does not represent the cost for 
different hospitals. All other anti-fragility hip fractures 
measures were not evaluated in this study as it is 
complex to put a cost to all these. They include steps 
taken to make homes safer such as attention to carpets 
and loose furniture. 
 
Conclusion 
Osteoporotic hip fractures are a common 
occurrence in the elderly population. These increase the 
overall morbidity and mortality in this sub population. 
Withstanding evidence based medicine; orthopaedic 
surgeons even nowadays still fail to prescribe anti-
osteoporotic treatment post surgical fixation of an 
osteoporotic hip fracture. There should be an increased 
drive through the Mater Dei policy makers, to institute 
anti-osteoporotic treatment. Prevention is better than 
cure; prescribing a bisphosphonate post-surgery may be 
more beneficial both to the patient and to the national 
health services with a decrease incidence of osteoporotic 
fractures and related morbidity and cost to the health 
services. 
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